Follow us on Twitter for more updates (http://twitter.com/#SmithOnStocks or if already on Twitter, search for @SmithOnStocks).

My name is Larry Smith. My career was spent on Wall Street as an analyst and also Director of Research, primarily at Smith Barney and Hambrecht and Quist. On my website, SmithOnStocks, I publish articles on biotechnology and pharmaceutical companies. The content in the Company Reports section of the website and the Blog is free to the public. In most cases, the reports on my website are more extensive and in-depth than those which I publish on Seeking Alpha. I also offer a subscription service that provides investment insights and detailed financial models on certain companies at a price ...More of $100.00 per year. Premium subscription services that provide direct access to the author at available at prices that are dependent on the service provided.

I attempt to be objective and present a balanced view of negatives and positives. I do buy healthcare stocks and consider myself a buy and hold, Warren Buffett type of investor. I do not like short term trading. I have just launched a new website called SmithOnStocks which is offered only on a subscription basis. This can be directly accessed from the Seeking Alpha website by clicking on SmithOnStocks Company which is shown below.

SmithOnStocks is not registered as a securities broker-dealer or as an investment adviser with the U.S. Securities and Exchange Commission or with any state securities regulatory authority. SOS relies solely on publicly disclosed and available information. While SOS makes all reasonable efforts to confirm the accuracy of its statements and opinions, all comments should be considered only as opinion and should not be considered to be absolute fact. Investors should carefully read the Terms & Conditions and Disclosures sections of my website. Investors should carefully perform their own due diligence, seek other points of view and consult with their broker or financial advisor.

Investing in equities includes considerable risk, and investors should be prepared for the possibility of capital loss. This is particularly the case with biotechnology stocks in which hard to predict clinical and commercial outcomes can often disappoint investors and lead to unusually large declines in price. Potential investors in biotechnology stocks must often be prepared to risk the loss of substantially all of their investment. These stocks are only suitable for investors willing and able to accept unusually high financial risk. Users of my information acknowledge that SOS and its owner are not liable to any person or entity for the accuracy, thoroughness, reliability, or timeliness of the information provided. Users further acknowledge that SOS is also not responsible for any direct or indirect losses that may arise from the use of information provided to any person or entity.

Employees of SmithOnStocks do buy and sell healthcare stocks, some of which may be the subject of written articles appearing on SOS. In the event that employees have a stock investment in a company, that ownership is fully disclosed.

See Seeking Alpha's policy on anonymous authors.